{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:57:01Z","timestamp":1791489421963,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":142,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101257","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:20:21Z","timestamp":1779549621000},"page":"101257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotoxin therapy: a promising frontier in targeted cancer treatment a review of clinical trials in hematological and solid tumors"],"prefix":"10.1016","volume":"48","author":[{"given":"Arash","family":"Abdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Sedighian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoleikha","family":"Goleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Fasihi-Ramandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Kachuei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas Ali Imani","family":"Fooladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctarc.2026.101257_bib0001","first-page":"150","article-title":"Texosome-based drug delivery system for cancer therapy: from past to present","volume":"12","author":"Hosseini","year":"2015","journal-title":"Cancer Biol. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101257_bib0002","article-title":"The role of epidermal growth factor receptor in cancer and their application for new targeted cancer therapy","volume":"12","author":"Maleki","year":"2018","journal-title":"J. Clin. Diagnostic Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0003","article-title":"Effect of metalloprotease arazyme on the expression of MMP2 and MMP9 genes in metastasis of colon and ovarian cancer cell lines","volume":"8","author":"Amjadi","year":"2020","journal-title":"Thrita"},{"key":"10.1016\/j.ctarc.2026.101257_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2023.105651","article-title":"Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro","volume":"92","author":"Gholipour","year":"2023","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ctarc.2026.101257_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1569502","article-title":"Clinically approved immunotoxins targeting hematological cancers:\"the best of both worlds\"","volume":"16","author":"Rashad","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101257_bib0006","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/17474086.2025.2546118","article-title":"Mucosal toxicity in hematological malignancies: prevention, management, and novel therapeutic insights","volume":"18","author":"Niscola","year":"2025","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0007","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13277-015-3877-1","article-title":"Staphylococcal enterotoxin B\/texosomes as a candidate for breast cancer immunotherapy","volume":"37","author":"Imani Fooladi","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ctarc.2026.101257_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105651","article-title":"Breast cancer targeted\/therapeutic with double and triple fusion Immunotoxins","volume":"200","author":"Goleij","year":"2020","journal-title":"J. Steroid Biochem. Mole. Biol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4155\/tde-2022-0055","article-title":"New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery","volume":"14","author":"Morgan","year":"2023","journal-title":"Therap. Deliv."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101257_bib0010","article-title":"In silico evaluation of two targeted chimeric proteins based on bacterial toxins for breast cancer therapy","volume":"12","author":"Goleij","year":"2019","journal-title":"Int. J. Cancer Manage."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/antib15010012","article-title":"Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody","volume":"15","author":"Kuhlmann","year":"2026","journal-title":"Antibodies"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101257_bib0012","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/toxins17100494","article-title":"Ricin and abrin in biosecurity: detection technologies and strategic responses","volume":"17","author":"Zajaczkowski","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.ctarc.2026.101257_bib0013","article-title":"Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0014","first-page":"27","article-title":"In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin","volume":"25","author":"Hosseininejad-Chafi","year":"2022","journal-title":"Iranian J. Basic Med. Sci."},{"key":"10.1016\/j.ctarc.2026.101257_bib0015","doi-asserted-by":"crossref","unstructured":"Tortorella LL, Pipalia NH, Mukherjee S, Pastan I, Fitzgerald D, Maxfield FR. Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0047320.","DOI":"10.1371\/journal.pone.0047320"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101257_bib0016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/toxins17090459","article-title":"Bacterial protein toxins as anticancer agents: clinical potential of Pseudomonas and anthrax toxins","volume":"17","author":"Misra","year":"2025","journal-title":"Toxins"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101257_bib0017","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00894-023-05562-z","article-title":"In silico and experimental methods for designing a potent anticancer arazyme-herceptin fusion protein in HER2-positive breast cancer","volume":"29","author":"Rahmani","year":"2023","journal-title":"J. Mole. Model."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1158\/1078-0432.CCR-12-1258","article-title":"Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer","volume":"19","author":"Yang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101257_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114801","article-title":"Nanobody-based immunotoxins: a precision tool in the treatment of solid tumors","volume":"158","author":"Emami","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro-Oncol."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101257_bib0021","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0022","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/1061186X.2021.1894435","article-title":"Immunotoxins and nanobody-based immunotoxins: review and update","volume":"29","author":"Khirehgesh","year":"2021","journal-title":"J. Drug Target."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101257_bib0023","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101257_bib0024","doi-asserted-by":"crossref","first-page":"gzaf003","DOI":"10.1093\/protein\/gzaf003","article-title":"Tuning ProteinMPNN to reduce protein visibility via MHC Class I through direct preference optimization","volume":"38","author":"Gasser","year":"2025","journal-title":"Protein Eng., Des. Sel.."},{"key":"10.1016\/j.ctarc.2026.101257_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1386190","article-title":"Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers","volume":"14","author":"Skorupan","year":"2024","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101257_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202408086","article-title":"GRP78 nanobody-directed immunotoxin activates innate immunity through sting pathway to synergize tumor immunotherapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ctarc.2026.101257_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125003","article-title":"Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity","volume":"669","author":"Wang","year":"2025","journal-title":"Int. J.Pharm."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101257_bib0028","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.4049\/jimmunol.1200656","article-title":"Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates","volume":"188","author":"Yamada","year":"2012","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101257_bib0029","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3324\/haematol.2012.071092","article-title":"Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195\/rGEL), in patients with advanced myeloid malignancies","volume":"98","author":"Borthakur","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101257_bib0030","first-page":"1779","article-title":"A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4. dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma","volume":"8","author":"Schnell","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101257_bib0031","doi-asserted-by":"crossref","unstructured":"Amlot P, Stone M, Cunningham D, Fay J, Newman J, Collins R, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. 1993. https:\/\/doi.org\/10.1182\/blood.V82.9.2624.2624.","DOI":"10.1182\/blood.V82.9.2624.2624"},{"key":"10.1016\/j.ctarc.2026.101257_bib0032","series-title":"Anti-CD3 immunotoxin to induce remissions in cutaneous T-cell lymphoma patients","author":"Frankel","year":"2012"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0033","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.leu.2401626","article-title":"Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin","volume":"14","author":"Schnell","year":"2000","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101257_bib0034","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101257_bib0035","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8_Supplement","key":"10.1016\/j.ctarc.2026.101257_bib0036","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1538-7445.AM10-5606","article-title":"Preclinical and clinical development of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia","volume":"70","author":"Singh","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101257_bib0037","first-page":"1004","article-title":"Phase I trial of a novel diphtheria toxin\/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia","volume":"8","author":"Frankel","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101257_bib0038","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/MPH.0b013e3181bdf211","article-title":"A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia","volume":"31","author":"Herrera","year":"2009","journal-title":"J.Pediatric Hematol.\/Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101257_bib0039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00002371-199511000-00004","article-title":"Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration","volume":"18","author":"Conry","year":"1995","journal-title":"J. Immunother."},{"issue":"27","key":"10.1016\/j.ctarc.2026.101257_bib0040","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101257_bib0041","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"New Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ctarc.2026.101257_bib0042","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101257_bib0043","doi-asserted-by":"crossref","unstructured":"LeMaistre C, Meneghetti C, Rosenblum M, Reuben J, Parker K, Shaw J, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in. 2011. https:\/\/doi.org\/10.1182\/blood.V79.10.2547.2547.","DOI":"10.1182\/blood.V79.10.2547.2547"},{"key":"10.1016\/j.ctarc.2026.101257_bib0044","series-title":"Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed\/refractory hairy cell leukemia","author":"Kreitman","year":"2021"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0045","first-page":"57","article-title":"Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clinical cancer research: an official journal of the","volume":"1","author":"Goldberg","year":"1995","journal-title":"Am. Assoc. Cancer Res."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101257_bib0046","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.1991.9.12.2095","article-title":"Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer","volume":"9","author":"Pai","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101257_bib0047","first-page":"3092","article-title":"A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors","volume":"8","author":"Posey","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101257_bib0048","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101257_bib0049","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101257_bib0050","doi-asserted-by":"crossref","first-page":"R617","DOI":"10.1186\/bcr1264","article-title":"Phase I clinical study of the recombinant antibody toxin scFv (FRP5)-ETA specific for the ErbB2\/HER2 receptor in patients with advanced solid malignomas","volume":"7","author":"von Minckwitz","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101257_bib0051","first-page":"2311","article-title":"Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor","volume":"5","author":"Pai-Scherf","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101257_bib0052","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/jnci\/djae017","article-title":"Developing the next-generation cancer research workforce in the National Institutes of Health Intramural Research Program","volume":"116","author":"Schor","year":"2024","journal-title":"JNCI: J. National Cancer Inst."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101257_bib0053","first-page":"1023","volume":"1","author":"Benhar","year":"1995","journal-title":"Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101257_bib0054","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1073\/pnas.92.7.2765","article-title":"Intrathecal administration of single-chain immunotoxin, LMB-7 [B3 (Fv)-PE38], produces cures of carcinomatous meningitis in a rat model","volume":"92","author":"Pastan","year":"1995","journal-title":"Proceed. National Acad. Sci."},{"issue":"14_suppl","key":"10.1016\/j.ctarc.2026.101257_bib0055","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/jco.2004.22.90140.3035","article-title":"Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): Results of phase I study of SS1 (dsFv) PE38 (SS1P)","volume":"22","author":"Hassan","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101257_bib0056","first-page":"349","article-title":"The preclinical and clinical evaluation of VB6-845: an immunotoxin with a de-immunized payload for the systemic treatment of solid tumors. antibody-drug Conjugates and immunotoxins: from pre-clinical Development to therapeutic applications","author":"Entwistle","year":"2012","journal-title":"Springer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0057","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00262-007-0363-7","article-title":"EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells","volume":"57","author":"Ochiai","year":"2008","journal-title":"Cancer Immunol., Immunother.."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0058","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1026290315809","volume":"65","author":"Sampson","year":"2003","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101257_bib0059","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1535-7163.MCT-08-1149","article-title":"Induction of programmed cell death in ErbB2\/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor","volume":"8","author":"Mahmud","year":"2009","journal-title":"Mole. Cancer Therapeutics"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0060","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1210\/jc.2009-0309","article-title":"Overexpression of interleukin-13 receptor-\u03b12 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy","volume":"94","author":"Lai","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101257_bib0061","first-page":"2157","article-title":"Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma","volume":"6","author":"Rand","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101257_bib0062","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.3390\/toxins2112519","article-title":"Toxin-based therapeutic approaches","volume":"2","author":"Shapira","year":"2010","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101257_bib0063","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clml.2012.01.011","article-title":"Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas","volume":"12","author":"Talpur","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.ctarc.2026.101257_bib0064","series-title":"Avalia\u00e7\u00e3o in vitro do potencial citot\u00f3xico da imunotoxina Moxetumomab pasudotox para o tratamento do linfoma canino","author":"Loureiro","year":"2022"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101257_bib0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.beha.2015.10.015","article-title":"Hairy cell leukemia: past, present and future","volume":"28","author":"Getta","year":"2015","journal-title":"Best Practice Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101257_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2007.11.006","article-title":"GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv (UCHT1) for phase I\/II clinical trials","volume":"58","author":"Woo","year":"2008","journal-title":"Protein Exp. Purif."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101257_bib0067","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.leukres.2009.02.006","article-title":"Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy","volume":"33","author":"Vallera","year":"2009","journal-title":"Leukemia Res."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101257_bib0068","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/bjc.2015.380","article-title":"Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin","volume":"113","author":"Andersson","year":"2015","journal-title":"British J. Cancer"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101257_bib0069","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J. Urol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0070","first-page":"1971","article-title":"Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clinical cancer research: an official journal of the","volume":"4","author":"Pagliaro","year":"1998","journal-title":"Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101257_bib0071","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101257_bib0072","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4111\/icu.20200602","article-title":"Emerging treatments for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"62","author":"Kim","year":"2021","journal-title":"Invest. Clin. Urol."},{"issue":"24","key":"10.1016\/j.ctarc.2026.101257_bib0073","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1021\/acs.jmedchem.2c00494","article-title":"Mechanism of action and structure-activity relationship of \u03b1-conotoxin mr1. 1 at the human \u03b19\u03b110 nicotinic acetylcholine receptor","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101257_bib0074","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-7091-6090-9_16","article-title":"Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies","author":"Kunwar","year":"2003","journal-title":"Local Therapies for Glioma Present Status and Future Developments"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101257_bib0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/01.cji.0000162782.86008.mL","article-title":"Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor","volume":"28","author":"Garland","year":"2005","journal-title":"J. Immunother."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101257_bib0076","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.ctarc.2026.101257_bib0077","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-12-3891","article-title":"Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy","volume":"19","author":"Chandramohan","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:48:59Z","timestamp":1790912939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":77,"alternative-id":["S2468294226001681"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101257","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotoxin therapy: a promising frontier in targeted cancer treatment a review of clinical trials in hematological and solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101257"}}